Agilent Technologies this week announced updates to its SurePrint miRNA Microarrays to include targets from the latest version of the miRBase public miRNA database. The database, miRBase 21, contains 28,645 entries including more than 15 percent in content added from miRBase 20, Agilent said.
The availability of Agilent SurePrint human, mouse, and rat miRNA microarrays with miRBase 21 targets provides pre-designed microarrays for the most commonly studied models, the company added. Any species in the miRBase database can also be used to create a custom microarray through the web-based design tool eArray to include probe content from the miRBase 21.
In a recently published study in Nature Methods, Agilent SurePrint miRNA Microarrays were compared with various qPCR, next-generation sequencing, and microarray platforms to benchmark performance. Starting with only 100 ng of total RNA, Agilent miRNA microarrays exhibited excellent performance with the highest titration response, reproducibility, and precision in accuracy while requiring the lowest sample amount among the next-closest performing assays.
SurePrint miRNA Microarrays are part of the SurePrint product family, including gene expression and comparative genomic hybridization microarrays.
BioNano Genomics this week said it has reached a major milestone for its Irys system: the ability to collect human data at 30X depth, sufficient for a genome map, in 24 hours on a single chip.
The company demonstrated this new capability for the IrysChip V2, the high-throughput chip for the Irys system, and will be rolled out to BioNano's collaborators and customers over the next two months, the company said.
The Irys system relies on the IrysChip to uncoil and confine long DNA molecules in proprietary nanochannel arrays, where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging, allowing users to analyze structural variation in human genomes and advance the finishing of genome assemblies.
BioNano is showcasing this advancement, dubbed "One Human: One Chip: One Day," at the American Society for Human Genetics annual meeting this week in San Diego, where the company also announced major software updates to IrysView and IrysSolve to improve visualization and analysis.
InDevR, a Boulder, Colo.-based life science company, this week announced that version 1.0 of the Influenza Titer on Chip is now available for purchase as a complete kit.
Flu-ToC is used as an alternative to single radial immunodiffusion for rapid quantification of influenza hemagglutinin protein in flu vaccines. The product uses a panel of subtype-specific antibodies that enable reliable quantification of hemagglutinin over a range of years, and can quantify HA protein in almost any medium including crude extract, bulk drug substance, and multivalent drug product, InDevR said.